100% Secure Checkout Secure
Third-Party HPLC Tested HPLC Tested
Accurately measure your GLP-1 receptor agonist research protocols. Enter your vial size, bacteriostatic water volume, and desired dose to calculate the exact syringe draw.
Standard Semaglutide vials are typically 2mg, 3mg, 5mg, or 10mg.
Volume of water used to reconstitute the lyophilized powder.
Semaglutide is often dosed in 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg increments.
Select the maximum capacity of your U-100 insulin syringe.
Draw exactly to the 10 unit mark (red line) on a 1mL (100 Unit) insulin syringe.
Concentration
2.50 mg/mL
Dose per Unit (1/100 mL)
25.0 mcg/Unit
Volume to Inject
0.10 mL
Select a research protocol below to view its specific week-by-week titration chart.
| Phase | Timeline | Weekly Dosage |
|---|---|---|
| Initiation | Weeks 1 - 4 | 0.25 mg |
| Titration 1 | Weeks 5 - 8 | 0.50 mg |
| Titration 2 | Weeks 9 - 12 | 1.0 mg |
| Maintenance | Weeks 13+ | 1.7 - 2.4 mg |
Standard clinical trial escalation. If GI side effects are intolerable at a new step, delay titration by an additional 2-4 weeks.
GLP-1 Receptor Agonist
A widely researched GLP-1 analogue known for effectively reducing appetite, improving insulin sensitivity, and supporting significant weight loss.
Semaglutide is an exceptionally long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the naturally occurring incretin hormone, directly targeting areas of the brain that regulate appetite and food intake.
By delaying gastric emptying and increasing glucose-dependent insulin secretion, it provides a dual-action mechanism for sustained metabolic control. It effectively alters the subject's relationship with food satiety signals.
Result: Dramatic reduction in caloric intake and vastly improved glycemic markers, leading to consistent, long-term adipose tissue reduction.
Lyophilized Semaglutide is highly fragile prior to reconstitution. Store unmixed vials in the freezer (-20°C) for long-term preservation. Once reconstituted with Bacteriostatic Water, the peptide must be refrigerated (2°C - 8°C) to prevent rapid degradation.
Semaglutide exhibits an extended half-life of approximately 7 days, perfectly supporting a once-weekly subcutaneous administration schedule.
Due to this pharmacokinetic profile, steady-state blood plasma concentrations are typically achieved after 4 to 5 weeks of continuous dosing. This is why the standard titration protocol requires 4 weeks at each dosage step before escalating.
Current pharmacological research models suggest Semaglutide should be strictly excluded in subjects with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Monitoring: Watch for signs of acute pancreatitis (severe abdominal pain radiating to the back) and potential gallbladder issues throughout the duration of the protocol.